Challenges to the development of disease‐modifying therapies in Parkinson’s disease
Identifieur interne : 000370 ( Main/Exploration ); précédent : 000369; suivant : 000371Challenges to the development of disease‐modifying therapies in Parkinson’s disease
Auteurs : A. H. V. Schapira [Royaume-Uni]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2011-03.
English descriptors
- KwdEn :
Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that involves the neurones of multiple transmitter pathways. The dopaminergic neuronal degeneration determines the main early clinical characteristics of the disease. There have been many recent valuable insights into the pathogenesis of PD, driven primarily by research of the genetic causes of the disease. These now provide a clearer view of the pathways that lead to neuronal dysfunction and death. Perhaps surprisingly, the same pathways initiated by gene mutations causing familial PD are those already identified to be involved in idiopathic sporadic PD, namely mitochondrial dysfunction, oxidative stress and protein misfolding and aggregation. Novel therapies designed to slow PD progression are likely to intervene in one or more of these pathways. Some candidates have been tested based upon this hypothesis, albeit with varying results. Significant developments in this area face several challenges including effective disease‐modelling systems and clinical trial designs that can enable a true positive result to be obtained in a relatively short period.
Url:
DOI: 10.1111/j.1468-1331.2010.03324.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Challenges to the development of disease‐modifying therapies in Parkinson’s disease</title><author><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7726EEE24BD30E1DF19CBC016DE3A920C367D414</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1468-1331.2010.03324.x</idno><idno type="url">https://api.istex.fr/document/7726EEE24BD30E1DF19CBC016DE3A920C367D414/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000412</idno><idno type="wicri:Area/Main/Curation">000357</idno><idno type="wicri:Area/Main/Exploration">000370</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Challenges to the development of disease‐modifying therapies in Parkinson’s disease</title><author><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurosciences, Institute of Neurology, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-03">2011-03</date><biblScope unit="volume">18</biblScope><biblScope unit="supplement">s1</biblScope><biblScope unit="page" from="16">16</biblScope><biblScope unit="page" to="21">21</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">7726EEE24BD30E1DF19CBC016DE3A920C367D414</idno><idno type="DOI">10.1111/j.1468-1331.2010.03324.x</idno><idno type="ArticleID">ENE3324</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson’s disease</term><term>autophagy</term><term>genes</term><term>mitochondria</term><term>neuroprotection</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson’s disease (PD) is a progressive neurodegenerative disorder that involves the neurones of multiple transmitter pathways. The dopaminergic neuronal degeneration determines the main early clinical characteristics of the disease. There have been many recent valuable insights into the pathogenesis of PD, driven primarily by research of the genetic causes of the disease. These now provide a clearer view of the pathways that lead to neuronal dysfunction and death. Perhaps surprisingly, the same pathways initiated by gene mutations causing familial PD are those already identified to be involved in idiopathic sporadic PD, namely mitochondrial dysfunction, oxidative stress and protein misfolding and aggregation. Novel therapies designed to slow PD progression are likely to intervene in one or more of these pathways. Some candidates have been tested based upon this hypothesis, albeit with varying results. Significant developments in this area face several challenges including effective disease‐modelling systems and clinical trial designs that can enable a true positive result to be obtained in a relatively short period.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000370 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000370 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7726EEE24BD30E1DF19CBC016DE3A920C367D414
|texte= Challenges to the development of disease‐modifying therapies in Parkinson’s disease
}}
| This area was generated with Dilib version V0.6.23. |  |